Navitas stock soars as company advances 800V tech for NVIDIA AI platforms
Investing.com -- Coloplast A/S (CSE:COLOb) on Tuesday said its net profit fell 26% in the first nine months of its 2024/25 financial year, as extraordinary tax expenses tied to its Kerecis unit outweighed sales and operating growth.
Net profit dropped to DKK 2.76 billion from DKK 3.74 billion a year earlier, while diluted earnings per share declined to DKK 12.25 from DKK 16.62.
Revenue for the period rose 4% to DKK 20.91 billion, supported by 7% organic growth.
Reported growth was cut by a 2% negative currency impact and a 1% effect from the Skin Care divestment.
Earnings before interest and tax increased 4% to DKK 5.72 billion, equal to a 27% margin, unchanged from last year.
Third-quarter revenue rose 1% to DKK 6.96 billion, with organic growth of 7%. EBIT before special items was DKK 1.92 billion, up 2% year over year, giving an EBIT margin of 28%, compared with 27% a year earlier.
By business segment, Ostomy Care grew 6% in the quarter, led by the SenSura Mio portfolio in Europe and the U.S., while China recorded low growth. Continence Care advanced 8%, driven by the Luja catheter line.
Voice and Respiratory Care rose 9% on demand for Laryngectomy and Tracheostomy products.
Advanced Wound Care declined 8% on reported revenue after a voluntary product return in China that reduced sales by about DKK 20 million.
Kerecis, part of Advanced Wound Care, increased 17%. Interventional Urology grew 4%, with gains in U.S. Men’s Health partly offset by a DKK 10 million revenue loss from a product recall in Bladder Health and Surgery.
Regional sales in the third quarter rose 4% in Europe, fell 1% in other developed markets, and dropped 7% in emerging markets.
For the nine months, Europe grew 5%, other developed markets 5%, and emerging markets 2%.
Gross profit for the nine months was DKK 14.18 billion, equal to a margin of 68%, on par with last year.
Operating expenses rose 4% to DKK 8.47 billion, with distribution costs increasing due to higher sales activity and logistics costs, while administrative expenses fell 3% to DKK 930 million. Research and development spending was stable at DKK 697 million.
Free cash flow improved to DKK 3.52 billion, compared with an outflow of DKK 186 million last year, due to lower tax payments.
Net interest-bearing debt stood at DKK 23.49 billion at the end of June, equal to 2.6 times EBITDA before special items.
The Danish medical device company kept its full-year outlook for about 7% organic revenue growth and an EBIT margin of 27-28% before special items.
Reported revenue growth is projected at 3-4%, including negative impacts from currency movements and the Skin Care divestment.
Capital expenditure is expected at about DKK 1.4 billion, with an effective tax rate of about 40% due to the Kerecis intellectual property transfer.